YCYi Fan Chen

Yi Fan Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yi Fan Chen has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Routine sequencing of BRAF exon 15 improves therapeutic stratification for metastatic melanoma

    by Yi Fan Chen, Arshna Qureshi, Jessica E Sigel, Navid Sadri

    Objective: BRAF V600E/K mutations are significant drivers of metastatic melanoma, and therapies that selectively target these mutations have significantly improved patient long-term survival. Emerging evidence suggests that tumors harboring BRAF non-V600E/K mutations are susceptible to MEK-targeting therapies, but these mutations are not always assessed in clinical workup. To assess whether patient stratification for targeted therapy can be improved, we characterized the prevalence and nature of BRAF non-V600E/K mutations in a cohort of patients diagnosed with metastatic melanoma. Methods: We extracted DNA from 99 specimens collected between June 2019 and September 2021. The samples were analyzed using next-generation sequencing to identify mutations in BRAF exon 15 and to assess their susceptibility to targeted therapies. Results: Eleven percent of patient specimens contained BRAF non-V600E/K mutations in exon 15. Of the mutations identified, all have prior evidence of susceptibility to targeted MEK therapies. Among those patients, less than half received targeted MEK therapies. Conclusions: Next-generation sequencing is a sensitive platform for profiling BRAF exon 15 mutations that cannot be detected by other techniques. Our results support the routine sequencing of BRAF exon 15 to improve patient stratification for therapy.

  • Prevalence of non- Helicobacter pylori Helicobacter (NHPH) species in H. pylori -associated gastritis

    by Yi Fan Chen, Aditi Tayal, Kenneth Friedman, Navid Sadri

    Helicobacter pylori is a well-established cause of gastritis and gastric malignancy, but other Helicobacter species—collectively termed non- Helicobacter pylori Helicobacter (NHPH)—also contribute to gastric disease. This study retrospectively analysed the prevalence of NHPH in 1115 routine gastric biopsies from a large academic medical centre submitted for H. pylori drug susceptibility genotyping using a next-generation sequencing (NGS) assay targeting 16S and 23S rRNA genes. NGS results of identified pathogens were compared against those identified on histology. NHPH species were detected in 15 of 1115 cases (1.3%), including 7 NHPH-only infections and 8 mixed infections with H. pylori . Detected NHPH species included Helicobacter heilmannii , Helicobacter felis and Helicobacter bizzozeronii . No mutations associated with antimicrobial resistance were identified in NHPH. Broader molecular testing may improve recognition of mixed infections and guide more accurate diagnosis and treatment for gastric disease.

  • XPO1-Targeting Selective Inhibitors of Transcriptional Activation Suppress Graft-versus-Host Disease

    by Yanqiu Shen, Yi Fan Chen, David F. Yan, Lyannah A. Contreras, Frederick N. Petroze, Ramya Srinivasan, Amanda N. Farrar, George L. Trainor, Amar B. Desai, Drew J. Adams

    Exportin-1 (XPO1) is a mediator of nuclear-to-cytoplasmic protein trafficking. The XPO1-targeting selective inhibitor of nuclear export (SINE) Selinexor is FDA-approved for relapsed hematological malignancies. Recently, we reported a unique class of XPO1 modulators that suppressed T cell activation without impairing nuclear export or cell viability (the selective inhibitors of transcriptional activation, or SITAs), suggesting that XPO1 may be a therapeutic target in T cell-driven diseases. Here, we analyzed structure-activity relationships of two structurally distinct subseries of SITAs. A set of pyridine-containing structures attained high cellular potencies (EC50 1 nM), while a complementary set of pyrrolotriazine-containing molecules balanced cellular potency with desirable physicochemical properties. Lead molecules from both subseries demonstrated in vivo XPO1 engagement, were efficacious in a mouse model of graft versus host disease, and showed superior tolerability to Selinexor. This study provides evidence that optimized XPO1-targeting SITAs can extend XPO1 as a therapeutic target to indications beyond oncology.


  • Electrophile Determines Cellular Phenotypes among XPO1-Targeting Small Molecules

    by Yi Fan Chen, Yanqiu Shen, David F. Yan, Maryam Ghazala, Marc A. Scemama de Gialluly, Ramya Srinivasan, Amanda N. Farrar, Ryan M. Friedrich, Drew J. Adams

    Covalent drug discovery has experienced a renaissance, with numerous electrophilic small molecules recently gaining FDA approval. Many structurally diverse electrophilic small molecules target exportin-1 (XPO1/CRM1) at cysteine 528, including the selective inhibitor of nuclear export (SINE) selinexor, which was FDA-approved as an anticancer agent in 2019. Emerging evidence supports additional pharmacological classes of XPO1 modulators targeting Cys528, including the selective inhibitors of transcriptional activation (SITAs) and probes that induce rapid degradation of XPO1. Here, we analyzed structure-activity relationships across multiple structural series of XPO1 Cys528-targeting probes. We observe that the electrophilic moiety of Cys528-targeting small molecules plays a decisive role in the cellular behavior observed, with subtle changes in electrophile structure being sufficient to convert XPO1-targeting probes to different pharmacological classes. This investigation represents a unique case study in which the electrophile functionality used to target a specific cysteine determines the pharmacological effect among diverse XPO1-targeting small molecules.


  • Targeting the chromatin binding of exportin-1 disrupts NFAT and T cell activation

    by Yi Fan Chen, Maryam Ghazala, Ryan M. Friedrich, Brittany A. Cordova, Frederick N. Petroze, Ramya Srinivasan, Kevin C. Allan, David F. Yan, Joel L. Sax, Kelley Carr, et al.

    Exportin-1 (XPO1/CRM1) plays a central role in the nuclear-to-cytoplasmic transport of hundreds of proteins and contributes to other cellular processes, such as centrosome duplication. Small molecules targeting XPO1 induce cytotoxicity, and selinexor was approved by the Food and Drug Administration in 2019 as a cancer chemotherapy for relapsed multiple myeloma. Here, we describe a cell-type-dependent chromatin-binding function for XPO1 that is essential for the chromatin occupancy of NFAT transcription factors and thus the appropriate activation of T cells. Additionally, we establish a class of XPO1-targeting small molecules capable of disrupting the chromatin binding of XPO1 without perturbing nuclear export or inducing cytotoxicity. This work defines a broad transcription regulatory role for XPO1 that is essential for T cell activation as well as a new class of XPO1 modulators to enable therapeutic targeting of XPO1 beyond oncology including in T cell-driven autoimmune disorders.